{"title":"抗vegf药物联合全视网膜光凝治疗糖尿病视网膜病变的疗效及预后：临床观察研究。","authors":"H-T Bi, Y Wang, T-T Wang","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Diabetic retinopathy (DR) remains a leading global cause of blindness, significantly affecting the quality of life of patients with diabetes. This clinical observational study was designed to comprehensively assess the synergistic effects of anti-vascular endothelial growth factor (anti-VEGF) drugs and panretinal photocoagulation (PRP) on the progression of DR and visual outcomes. A total of 120 patients with severe non-proliferative or proliferative DR were prospectively recruited and randomly assigned into two groups: the combination therapy group (anti-VEGF + PRP) and the PRP monotherapy group. The results clearly demonstrated that the combination group achieved remarkable anatomical and functional improvements, with a more substantial reduction in macular edema and neovascularization. Long-term follow-up over 24 months further revealed better visual acuity retention and a lower incidence of complications in the combination group. These findings strongly support the integration of anti-VEGF agents into traditional PRP protocols for the effective management of advanced DR.</p>","PeriodicalId":12610,"journal":{"name":"Georgian medical news","volume":" 360","pages":"6-8"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"EFFICACY AND PROGNOSIS OF ANTI-VEGF AGENTS COMBINED WITH PANRETINAL PHOTOCOAGULATION IN DIABETIC RETINOPATHY: A CLINICAL OBSERVATIONAL STUDY.\",\"authors\":\"H-T Bi, Y Wang, T-T Wang\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Diabetic retinopathy (DR) remains a leading global cause of blindness, significantly affecting the quality of life of patients with diabetes. This clinical observational study was designed to comprehensively assess the synergistic effects of anti-vascular endothelial growth factor (anti-VEGF) drugs and panretinal photocoagulation (PRP) on the progression of DR and visual outcomes. A total of 120 patients with severe non-proliferative or proliferative DR were prospectively recruited and randomly assigned into two groups: the combination therapy group (anti-VEGF + PRP) and the PRP monotherapy group. The results clearly demonstrated that the combination group achieved remarkable anatomical and functional improvements, with a more substantial reduction in macular edema and neovascularization. Long-term follow-up over 24 months further revealed better visual acuity retention and a lower incidence of complications in the combination group. These findings strongly support the integration of anti-VEGF agents into traditional PRP protocols for the effective management of advanced DR.</p>\",\"PeriodicalId\":12610,\"journal\":{\"name\":\"Georgian medical news\",\"volume\":\" 360\",\"pages\":\"6-8\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Georgian medical news\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Georgian medical news","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
EFFICACY AND PROGNOSIS OF ANTI-VEGF AGENTS COMBINED WITH PANRETINAL PHOTOCOAGULATION IN DIABETIC RETINOPATHY: A CLINICAL OBSERVATIONAL STUDY.
Diabetic retinopathy (DR) remains a leading global cause of blindness, significantly affecting the quality of life of patients with diabetes. This clinical observational study was designed to comprehensively assess the synergistic effects of anti-vascular endothelial growth factor (anti-VEGF) drugs and panretinal photocoagulation (PRP) on the progression of DR and visual outcomes. A total of 120 patients with severe non-proliferative or proliferative DR were prospectively recruited and randomly assigned into two groups: the combination therapy group (anti-VEGF + PRP) and the PRP monotherapy group. The results clearly demonstrated that the combination group achieved remarkable anatomical and functional improvements, with a more substantial reduction in macular edema and neovascularization. Long-term follow-up over 24 months further revealed better visual acuity retention and a lower incidence of complications in the combination group. These findings strongly support the integration of anti-VEGF agents into traditional PRP protocols for the effective management of advanced DR.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
